Emerging Applications of CAR T-cell Therapy in Cancer
This activity consists of a recorded presentation from the "Essentials of Oncology, Solid Organ and Blood/Marrow Transplant Management for the Health Care Team" conference held in Scottsdale, Ariz., March 14–15, 2022.
Chimeric antigen receptor (CAR) T-cell therapy, based on the introduction of genetically modified autologous T cells that recognize tumor antigens and proliferate, has recently been approved for the treatment of relapsed and refractory multiple myeloma. It has previously been approved for hematologic malignancies, including subtypes of acute leukemia and non-Hodgkin lymphoma. Now, CAR T-cell therapy is also being investigated for the treatment of other hematologic cancers, and new research has emerged on its potential ability to treat solid tumors. This session will explore the most recent advances of this rapidly evolving therapy, including current data on its efficacy, limitations and challenges in the treatment of multiple myeloma and solid tumors. It will provide an overview of currently existing guidelines for CAR T-cell therapy and will describe best practices in determining individuals’ eligibility for this type of therapy, including factors that may affect treatment efficacy and outcomes.
This activity is provided by OptumHealth Education.
There was no commercial support for this activity.
Please ensure you are using the web-browser Chrome and disable any pop-up blocking software. Click here for information on how to enable pop-ups.
This activity is designed to meet the educational needs of case managers, nurses, pharmacists, pharmacy technicians, physicians, psychologists, social workers, dietitians, and other health care professionals who are interested in CAR T-cell therapy.
At the end of this educational activity, participants should be able to:
- Outline the principles of CAR T-cell therapy, including its mechanism of action and cellular targets.
- Describe current data about the recent and emerging applications of CAR T-cell therapy in multiple myeloma, other hematologic cancers, and solid tumors.
- Discuss the limitations and challenges of CAR T-cell therapy, including common side effects and toxicities.
- Report on the guidelines available for determining treatment strategies using CAR T-cell therapy.
- Identify factors that should be considered when determining individuals’ eligibility for, and potential benefit from, CAR T-cell therapy.
Veronika Bachanova, MD, PhD
Professor of Medicine
Section Head Hematologic Malignancy
Division of Hematology, Oncology and Transplantation
University of Minnesota
About the presenter
Dr. Veronika Bachanova centers her clinical practice around patients with blood cancers such as lymphoma and leukemia. She cares deeply for her patients and strives to apply the most effective and promising treatment options and methods. Along with the Bone Marrow and Cell Therapy Program team at the University of Minnesota Medical Center, she provides access to hematopoietic cell transplantation, immunotherapies and novel cellular therapies.
In her clinical practice, she witnesses every day the life-saving potential of transplantation and the capacity of the immune system to eliminate cancer. As a result, her clinical research is focused on the design and development of new approaches which utilize the immune system to attack cancer cells. Currently, she directs the team that is focused on the emerging field of CAR T-cell therapies and natural killer cellular therapies for the treatment of lymphoma and myeloma.
Elizabeth Albert, MD
Clinical Activity Manager
Eden Prairie, MN
Matthew Cooper, MD
President, UNOS Board of Directors;
Director, Kidney and Pancreas Transplantation
Medstar Georgetown Transplant Institute;
Professor of Surgery
Georgetown University School of Medicine
Rebecca Gleason, RN, CCM
Eden Prairie, MN
Alan N. Langnas, DO, FACS
Professor of Surgery
Director, Center of Transplantation
Chief, Section of Transplantation,
Department of Surgery
University of Nebraska Medical Center;
Director of Liver Transplantation
C. Fred LeMaistre, MD
Senior Vice President
Senior Vice President, Market Operations
Tina Rydland, PharmD
Disclosures of relevant financial relationships
In accordance with the Accreditation Council for Continuing Medical Education's (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, OptumHealth Education (OHE) requires all those in control of educational content to disclose their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are defined by the ACCME as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. Individuals must disclose all financial relationships, regardless of the amount, with ineligible companies and regardless of their view of the relevance of the relationship to the education. OHE ensures that the content is independent of commercial bias.
Dr. Bachanova has indicated that she is on the advisory board for Gamida Cell and receives grant/research funding from Gamida Cell, Incyte and FATE Therapeutics.
The activity planners have no financial relationships to disclose.
Method for calculating CE credit
CE credit was calculated by the complexity of content.
In support of improving patient care, OptumHealth Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.
Credit designation statements
This activity was planned by and for the health care team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credits for learning and change.
The participant will be awarded up to 1.0 contact hour(s) of credit for attendance and completion of supplemental materials.
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts credit from organizations accredited by the ACCME and ANCC.
This activity is approved for 1.0 contact hour(s) ([0.10] CEU) in states that recognize ACPE.
Attending the full program will earn 1.0 contact hour(s).
Unique Activity Number(s): JA0007123-0000-22-148-H01-P/T
OptumHealth Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Academy of Physician Assistants (AAPA) accepts credit from organizations accredited by the ACCME.
The Commission for Case Manager Certification has approved this program for a maximum of 1.0 clock hour(s) for Certified Case Managers (CCM).
Completion of this RD/DTR profession-specific or IPCE activity awards CPEUs (One IPCE credit=One CPEU).
If the activity is dietetics-related but not targeted to RDs or DTRs, CPEUs may be claimed which are commensurate with participation in contact hours (One 60 minute hour=1 CPEU).
RD's and DTRs are to select activity type 102 in their Activity Log. Performance indicator selection is at the learner's discretion.
Psychologists and social workers
Participants must have attended the entire Web-based activity and completed an evaluation to receive a certificate. Partial credit is not available.
OptumHealth Education is approved by the American Psychological Association (APA) to offer continuing education for psychologists. OptumHealth Education maintains responsibility for this program. 1.0 CE hour.
As a Jointly Accredited Organization, OptumHealth Education is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. OptumHealth Education maintains responsibility for this course. Social workers completing this course receive 1.0 enduring continuing education credit.
A certificate of attendance will be provided to learners upon completion of activity requirements, enabling participants to register with licensing boards or associations that have not been preapproved for credits. To apply for credit types not listed above, participants should use the procedure established by the specific organization with which they wish to obtain credit.
- 1.00 ACPE - Pharmacists
- 1.00 ACPE - Pharmacy Technicians
- 1.00 AMA - Physicians
- 1.00 ANCC - Nurses
- 1.00 APA - Psychologists
- 1.00 Attendance - General Attendance
- 1.00 CCMC - General - Case Managers
- 1.00 CDR - Dietitians
Prior to beginning this activity, please ensure you are using the web-browser Chrome and disable any pop-up blocking software. Click here for information on how to enable pop-ups.
You must be logged into your account to participate in this activity. Get started by clicking the down arrow and then "Start" under “Webcast”; then follow the prompts at the bottom of the screen. At the end of the activity, you will be able to view, save or print your certificate of participation. A complete listing of all of your activities can be found under “My Account,” “My Activities.”